云南白药集团股份有限公司第十一届董事会2026年第一次会议决议公告

Core Viewpoint - Yunnan Baiyao Group Co., Ltd. held its first board meeting of 2026 on February 10, 2026, where several key resolutions were passed to enhance production capacity and organizational structure, as well as appoint new executives to support the company's strategic goals [1][3][5]. Group 1: Project Approvals - The board approved the construction of the second phase of the oral liquid project at Wenshan Company with a total investment budget of 137.36 million yuan to meet the growing market demand for products like Qihuo Liquid [1]. - The board also approved the 2026 organizational structure plan to strengthen the implementation of strategic planning and operational goals [3]. Group 2: Executive Appointments - The board appointed Dong Ming as the CEO, Qian Yinghui as the board secretary, and Li Mengjue as the securities affairs representative, with a term of three years [5]. - Additionally, the board appointed several senior management personnel, including Li Hongshen, Li Shengli, He Tao, and Chen Shi as senior vice presidents, and Ma Jia as the financial director [8]. Group 3: Personnel Changes - Li Jin will no longer serve as a senior management member due to reaching the legal retirement age, and the company expressed gratitude for his contributions during his tenure [10][11]. - The company also announced the hiring of Zhu Zhaoyun as the strategic scientist for traditional Chinese medicine and Zhang Ning as the chief scientist to enhance its modern research and development capabilities [21].